Deferred Tax Assets, Valuation Allowance of REGENEREX PHARMA, INC. from 31 Mar 2017 to 31 Mar 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: REGENEREX PHARMA, INC. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Mar 2017 to 31 Mar 2025.
REGENEREX PHARMA, INC. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Mar 2025 was $1,582,654, a 51% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

REGENEREX PHARMA, INC. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2025	$1,582,654	+$537,054	+51%	31 Mar 2025	10-K	30 Jun 2025	2024	FY
Q1 2024	$1,045,600	+$685,500	+190%	31 Mar 2024	10-K	30 Jun 2025	2024	FY
Q1 2023	$360,100	+$29,200	+8.8%	31 Mar 2023	10-K	24 Jun 2024	2023	FY
Q1 2022	$330,900	+$38,200	+13%	31 Mar 2022	10-K	09 Jun 2023	2023	FY
Q1 2021	$292,700	+$22,700	+8.4%	31 Mar 2021	10-K	23 Jun 2021	2020	FY
Q1 2020	$270,000	+$21,000	+8.4%	31 Mar 2020	10-K	23 Jun 2021	2020	FY
Q1 2019	$249,000	+$488,000		31 Mar 2019	10-K/A	11 Aug 2020	2019	FY
Q1 2018	$239,000	+$146,000	+38%	31 Mar 2018	10-K	24 Jun 2019	2018	FY
Q1 2017	$385,000			31 Mar 2017	10-K	21 Jun 2018	2017	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.